NICE approves stomach tumour treatment
Sunitinib has been recommended by NICE for gastro-intestinal stromal tumours after a pricing deal with maker Pfizer.
Free to view - simply register with HSJ
Register once to read this article and get access to other registered-user content for free.
This content is free for all registered users to view.
If you have previously registered with HSJ, please enter your email address below.
Not yet registered?
Our registration process is simple and quick, and by registering once you get ongoing access to online content available only to HSJ registered users.
Get full access - now
Subscribe now for immediate access to hsj.co.uk and Health Service Journal magazine
